Hydroxytyrosol and heart function

What 2 graded rows on hydroxytyrosol agree on for heart function, and where they differ. Counted side by side, never averaged.

Consensus finder Rows from the Hydroxytyrosol page, reviewed Oct 21, 2026 How it decides

What the rows agree on

Each block and row is one graded row from the Hydroxytyrosol page, with its PubMed record.

Your question

Heart function2

Supplement

Hydroxytyrosol Choose another

Hydroxytyrosol and heart function

2 rows · 91 people

Split. 1 row found an improvement and 1 found no difference.

No difference

Improved

Each block is one evidence row, sized by how many people it enrolled, with its grade inside.

Grade D× 1
No effect× 1

Rows: 2
Trials: 2
People: 91

Where they differ

From the rows

Trial sizeWho was studied

The best-graded row, grade D, is a crossover trial of 30 people (2023) and found an improvement. 1 row is graded No effect, our grade for adequately powered trials that found no effect.

The row that found no difference was larger: 61 people, against 30 people for the row that found an improvement.

Only the row that found no difference names older adults in its population.

The rows

1 improved · 1 no difference

Grade DEndothelial and arterial function in chronic coronary syndrome · Improved
Crossover RCT · n 30 · 2023 · Patients with chronic coronary artery syndrome
4 capsules a day (10 mg hydroxytyrosol) · 1 month per period
Glycocalyx thickness, flow-mediated dilation, coronary flow reserve and pulse wave velocity improved from baseline with hydroxytyrosol but not with placebo; malondialdehyde, oxidised LDL, triglycerides, PCSK9 and CRP fell, in contrast to placebo. Blood pressure did not change.
Row on the Hydroxytyrosol page · PubMed 36912212 (opens PubMed)
No effectHeart function and arterial stiffness in chronic coronary artery disease · No difference
Crossover RCT · n 61 · 2023 · Patients with chronic coronary artery disease, aged 70 or younger
Two capsules a day (10 mg hydroxytyrosol) · 30 days per period
No significant change in left atrial or left ventricular function, central aortic pressure or augmentation index versus placebo; E/e′ (p = 0.062) and pulse wave velocity (p = 0.091) only trended toward improvement.
Row on the Hydroxytyrosol page · PubMed 37967452 (opens PubMed)

Read onRead the full evidenceThe full evidence chapter on its page, with every outcome and its sources.